Arvee Laboratories (India) share news, announcements and annual reports
NSE: ARVEEChemicals & PetrochemicalsSmall Cap
Arvee Laboratories (India) Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2018 · Issue price ₹61
Last close ₹206.71up ₹9.84 (5.00%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹196.87.
30 Oct: open ₹205.00, high ₹206.71, low ₹199.00
52-week range of traded prices to 30 Oct 2026
₹129.11Low, 30 Mar 2026₹290.78High, 19 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹228 Cr2,476th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 56.23
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.74
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,97864.8% delivered
Arvee Laboratories (India) disputes and clarifications
31 filed, newest first.
Oct 2026
Apr 2026
15 Apr · Legal
The exchange asked on 13 Apr 2026
Mar 2026
Dec 2025
24 Dec · Legal
The exchange asked on 19 Dec 2025
Oct 2024
30 Oct · Legal
The exchange asked on 29 Oct 2024
Apr 2024
8 Apr · Legal
Significant movement in price has been observed in Arvee Laboratories (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Dec 2023
11 Dec · Legal
The exchange asked on 11 Dec 2023
Jun 2023
21 Jun · Legal
Significant movement in price has been observed in Arvee Laboratories (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Apr 2023
18 Apr · Legal
The exchange asked on 17 Apr 2023
Dec 2022
8 Dec · Legal
The exchange asked on 7 Dec 2022
Jul 2022
7 Jul · Legal
The exchange asked on 6 Jul 2022
Mar 2022
12 Mar · Legal
The exchange asked on 11 Mar 2022
Aug 2021
Jul 2021
19 Jul · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 17-Jul-2021, regarding board meeting held on July 17, 2021. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment of internal auditor) The response of the Company is awaited.
Jun 2021
21 Jun · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Apr 2021
Mar 2021
30 Mar · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 26-Mar-2021, regarding sale of its entire investment in its wholly owned subsidiary Company namely Arvee Speciality Chemicals Private Limited.On basis of above the Company is required to clarify following: 1. The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;2. Date on which the agreement for sale has been entered into;3. The expected date of completion of sale/disposal;4. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.5. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";6. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.The response of the Company is awaited.
Dec 2020
Nov 2020
12 Nov · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Balance sheet statement not submitted -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2020
Jun 2020
30 Jun · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 27-Jun-2020, regarding "Intimation of appointment of Mr PARAGBHAI MANUBHAI SHAH as Non- Executive Independent Director of the company w.e.f. Jun 27, 2020."On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Dec 2019
2 Dec · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2019
Jun 2019
26 Jun · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 24-Jun-2019, regarding cessation of Mr SAUMIL BHARATBHAI CHOKSHI as Director of the company w.e.f. Jun 24, 2019. On basis of above the Company is required to clarify following: 1. In case of Independent Director, provide a confirmation that there is no other material reason for resignation 2. Reason for resignation. The response of the Company is awaited.
Jan 2019
Nov 2018
21 Nov · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
May 2018
11 May · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 11-May-2018, regarding " Arvee Laboratories (India) Limited has informed the Exchange regarding Appointment of Mr Saurin A Gandhi as Chief Financial Officer of the company w.e.f. May 10, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.